Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/11/2017 12/12/2017 12/13/2017 12/14/2017 12/15/2017 Date
141.14(c) 142.6(c) 142.89(c) 141.65(c) 142.46(c) Last
4 358 620 8 016 720 6 118 375 5 337 934 12 012 749 Volume
+0.39% +1.03% +0.20% -0.87% +0.57% Change
More quotes
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,35%
Sales 2018 80 683 M
EBIT 2018 25 840 M
Net income 2018 19 579 M
Debt 2018 7 337 M
Yield 2018 2,52%
P/E ratio 2017 23,89
P/E ratio 2018 19,64
EV / Sales2017 5,24x
EV / Sales2018 4,83x
Capitalization 383 B
More Financials
Company
Johnson & Johnson is an investment holding company with interests in health care products.It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment.The company operates through the following business segments: Consumer,... 
Sector
Pharmaceuticals
Calendar
01/23 | 12:40pmEarnings Release
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
12/15 JOHNSON & JOHNSON : ordered to pay $15M in vaginal mesh case
12/15 CONSUMERS ENERGY : Newsweek Ranks Consumers Energy as #1 Company in Michigan in ..
12/15 JOHNSON & JOHNSON : Jury awards $15 million in j&j trial
12/15 JOHNSON & JOHNSON : Janssen and Leading Advocacy Organizations Introduce Cancer...
12/14 JOHNSON & JOHNSON : Los Alamos research fundamental to first efficacy study for ..
12/14 JOHNSON & JOHNSON : Innovation Announces Launch of JLABS @ Shanghai in Collabora..
12/14 JOHNSON & JOHNSON : Bergen jury gets pelvic mesh case
12/14 JOHNSON & JOHNSON : and 4mm Navigational Bi-Directional Ablation catheters
12/14 JOHNSON & JOHNSON : J&Js Darzalex shows promise in newly-diagnosed multiple myel..
12/14 JOHNSON & JOHNSON : J&J`s Darzalex cuts risk of disease progression and death by..
More news
Sector news : Pharmaceuticals - NEC
12:38a PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
12:38a NELSON PELTZ : P&G appoints Peltz to board despite losing proxy battle
12/15 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
12/15DJSTOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on JOHNSON & JOHNSON 
JOHNSON & JOHNSON - 06/12
The underlying trend is to the upside
BUY
JOHNSON & JOHNSON - 05/10
Expect the comeback of a strong trend
BUY
More Strategies
News from SeekingAlpha
12/15 Just Turned 40? How To Reach A Goal Of $1.5 Million.
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Let Hitters Swing For The Fence
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 Johnson & Johnson (JNJ) Presents at BMO Capital Markets Prescriptions for Suc..
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON22.95%382 722
NOVARTIS13.16%222 673
PFIZER12.81%217 327
ROCHE HOLDING LTD.3.91%211 657
MERCK AND COMPANY-4.86%152 759
AMGEN21.32%126 976